Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

IPSSWM (Waldenström)

The IPSSWM stratifies patients with symptomatic Waldenström Macroglobulinemia into three risk groups based on Age, Beta-2 Microglobulin, Platelet count, Hemoglobin, and IgM level.

Evidence-based context for fast calculator use

Purpose:
IPSSWM stratifies Waldenstrom macroglobulinemia patients into prognostic risk groups to guide initiation of chemoimmunotherapy treatment.
Population:
patients with the specific hematologic diagnosis and disease phase described by the model
Factors:
Age > 65 years?, Beta-2 Microglobulin > 3 mg/L?, Hemoglobin ≤ 11.5 g/dL?, Platelets ≤ 100 x 10⁹/L?, Serum IgM > 7.0 g/dL?
Reference:
Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-4170.
HomeIPSSWM (Waldenström)
Pin your most used calculators here by clicking the star in the dropdown.

IPSSWM (Waldenström)

Clinical Context & Background

The IPSSWM stratifies patients with symptomatic Waldenström Macroglobulinemia into three risk groups based on Age, Beta-2 Microglobulin, Platelet count, Hemoglobin, and IgM level.
Primary Source EvidenceMorel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009;113(18):4163-4170.
Formula Logic
Risk factors: Age >65, B2M >3, Plt <100, Hb <11.5, IgM >7.

Reference Data

Risk GroupRisk Factors5-Year Survival
LowAge ≤ 65 + 0/1 adverse factor (except Age)87%
IntermediateAge > 65 + 0/1 adverse factor OR Age ≤ 65 + 2 factors68%
HighAge > 65 + ≥ 2 factors OR Age ≤ 65 + ≥ 3 factors36%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use IPSSWM (Waldenström) when iPSSWM stratifies Waldenstrom macroglobulinemia patients into prognostic risk groups to guide initiation of chemoimmunotherapy treatment.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Low through High.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm morphology, molecular/cytogenetic data, treatment timing, laboratory units, and the current disease-specific guideline before acting.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Hematology scores are diagnosis-, phase-, and treatment-specific and should not be transferred between diseases.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with the specific hematologic diagnosis and disease phase described by the model

How to apply this result

For a representative case, verify Age > 65 years?, Beta-2 Microglobulin > 3 mg/L?, Hemoglobin ≤ 11.5 g/dL?, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Hematology hubContinue to related calculators and clinical workflow resources.

Share This Calculator

Share:

Related Tools

NCCN-IPI (Lymphoma)CLL-IPIMIPI (Mantle Cell Lymphoma)

Frequently Asked Questions

When should IPSSWM (Waldenström) be used?

Use it for patients with the specific hematologic diagnosis and disease phase described by the model when all required inputs and the intended clinical setting are confirmed.

Can IPSSWM (Waldenström) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.